Degradable Microcapsules for Controlled Therapeutic Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled release systems for bioactive molecules face limitations in chemical flexibility and practicality for in vivo applications, with challenges in timing and release kinetics, and existing microencapsulation technologies for therapeutic cells have limitations in biocompatibility and immunogenicity.
Innovation Solution
Development of semipermeable microcapsules made of degradable polymers, such as cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride, containing genetically engineered cells that express cellulase in response to triggering compounds like doxycycline or luteinizing hormone, allowing controlled release of therapeutic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If chemically designed polymers are used for controlled release, then sustained release over time is achieved, but chemical flexibility is limited
Solution Approach 1:
The patent employs composite polymer systems combining degradable polymers (such as polylactic acid, polyglycolic acid, or their copolymers) with functional additives and crosslinking agents. This composite approach enables both sustained release capability through the degradable matrix and chemical flexibility through adjustable composition ratios, crosslinking densities, and incorporated functional groups that can be tailored to specific drug release requirements.
2Loss of time
If physical stimuli-responsive polymers are used, then release timing can be controlled, but practicality for in vivo applications is poor
Solution Approach 1:
The patent replaces complex external physical stimulus delivery systems (such as light sources, magnetic fields, or electrical leads required for in vivo application) with intrinsic biochemical sensing mechanisms. The polymer system responds to naturally occurring physiological triggers such as pH changes, enzyme presence, or redox conditions at the target site, eliminating the need for external stimulation equipment and enabling practical in vivo deployment.
Solution Approach 2:
The microcapsule system performs self-triggered release by detecting and responding to the local physiological environment automatically. The degradable polymer matrix autonomously senses changes in pH, enzyme concentration, or other biochemical markers and initiates drug release without external intervention, allowing the system to function independently once implanted in the patient's body.
3Reliability
If conventional encapsulation materials are used, then cell protection is achieved, but biocompatibility and immunogenicity are compromised
Solution Approach 1:
The patent applies local quality modification by creating a gradient or layered capsule wall structure where the outer layer consists of highly biocompatible, immunologically inert materials (such as dextran, gelatin, or collagen) that provide immune protection, while the inner layer contains the degradable polymer matrix that provides mechanical support and controlled release functionality. This spatial differentiation allows the capsule to simultaneously achieve cell protection and low immunogenicity.
Solution Approach 2:
The patent modifies the chemical and physical parameters of the encapsulation materials by adjusting molecular weight, degree of crosslinking, porosity, and surface charge to optimize both protective and immunological properties. For example, controlling the crosslinking density adjusts mesh size to protect cells while maintaining permeability to nutrients, and modifying surface properties reduces immune recognition without compromising structural integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microcapsules provide a biocompatible, immunologically non-reactive, and controlled release of therapeutic agents, enhancing the efficacy of treatments by adjusting release kinetics and timing, and improving the survival and functionality of encapsulated cells and sperm in therapeutic applications.
Implementation Method 1
a polymer degradable by a polypeptide comprising a genetically engineered cell expressing said polypeptide
Implementation Method 2
cellulase in response to triggering compounds
Implementation Method 3
nutrients, waste products and therapeutics may freely penetrate the semi-permeable membrane of capsules
Implementation Method 4
semi-permeable membrane
Data Source
Figure 1A~1B
Figure 1C
Figure 1D~1E
AI summary
The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate / poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.